Harvard Bioscience (FRA:HBI0) Tariff Resilience Score: 5/10 (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HBI0 Harvard Bioscience Inc FRA:HBI0
53 GF Score
Price €4.08
GF Value €6.70
! 9 Warning Signs
View Full Analysis

What is Harvard Bioscience Tariff Resilience Score?

Harvard Bioscience FRA:HBI0 53 Tariff Resilience Score is 5 as of Aug. 24, 2026. GuruFocus rates FRA:HBI0 with a GF Score™ of 53/100 and a GF Value™ of €6.70. The stock has 9 warning signs investors should review. Among 827 Medical Devices & Instruments companies, Harvard Bioscience ranks better than 79.2% on this metric.

Harvard Bioscience has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Harvard Bioscience has Relies on global supply chains for manufacturing scientific instruments. Moderate exposure to tariffs, but mitigated by diverse supplier base and potential pricing power.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Harvard Bioscience might have Average Resilient.

Harvard Bioscience  (FRA:HBI0) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Harvard Bioscience Tariff Resilience Score Related Terms

FRA:HBI0 vs RVP, MLSS, ZJYL: Tariff Resilience Score Comparison

For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harvard Bioscience Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Harvard Bioscience's Tariff Resilience Score falls into.


FRA:HBI0
53GF Score
Harvard Bioscience Inc FRA:HBI0
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Harvard Bioscience (FRA:HBI0) has a Tariff Resilience Score of 5 as of Aug. 24, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Harvard Bioscience ranks #172 out of 827 companies in the Medical Devices & Instruments industry, placing it in the top 20.8%.
Is Harvard Bioscience's Tariff Resilience Score too high?
Harvard Bioscience's current Tariff Resilience Score is 5. Based on the distribution chart, Harvard Bioscience ranks #172 out of 827 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Harvard Bioscience has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Tariff Resilience Score compare to RVP and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #172 out of 827 companies for Tariff Resilience Score. This places Harvard Bioscience in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Harvard Bioscience's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current Tariff Resilience Score of 5. The stock's GF Value™ is €6.70, compared to a current price of €4.08 — trading 39.1% below its estimated fair value. The current Tariff Resilience Score is 5. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current Tariff Resilience Score is 5 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued. The current stock price of €4.08 is trading 39.1% below its estimated GF Value™ of €6.70.

Key valuation signals for FRA:HBI0:

  • Tariff Resilience Score: 5
  • GF Value™: €6.70 vs. price of €4.08 (39.1% below fair value)
  • GF Score™: 53/100 with 9 warning signs

No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harvard Bioscience Business Description

Other Exchanges HBIO:USA
Address 84 October Hill Road, Suite 10, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score

Get the complete analysis for FRA:HBI0

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€6.70
GF Value